title: [Gefitinib for non-small cell lung cancer: a meta analysis].
abstract: OBJECTIVE
  Malignant grade and death rate are very high for non-small cell lung cancer, and gefitinib is a new molecule target anticancer drug. The aim of this meta analysis is to evaluate the clinical efficacy and safety of gefitinib for non-small cell lung cancer.
  
  
  METHODS
  We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 8, 2010), PubMed (1966-2010.8), EMBASE (1974-2010.8), CNKI (1994-2010.8), VIP (1989-2010.8), and CMD Digital Periodicals (1998-2010.8). Two reviewers independently evaluated the quality of the included studies and extracted the data. Meta-analyses were performed by RevMan 5.0 software.
  
  
  RESULTS
  Thirteen randomized controlled trials (RCTs) involving 6,207 patients were included. The results of meta-analyses showed that: gefitinib showed no remarkable advantage in media survival time, 1 year survival rate, complete response rate (CRR), partial response rate (PRR), stable disease (SD) when compared to Placebo, Docetaxel, Cisplatin+Docetaxel, Pemetrexed. Gifitinib could increase overall survival rate compared to Docetaxel, Cisplatin+Docetaxel (RR=1.41, 95%CI: 1.10-1.80; RR=1.93, 95%: 1.26-2.94). When compared to Placebo, Docetaxel, gifitinib could improve life quality of Total-FACT-L improve rate (RR=1.42, 95%CI: 1.16-1.74; RR=1.66, 95%CI: 1.39-1.97). The major adverse event for gifitinib were rash/acne, dry skin, diarrhea. While gifitinib showed lower hematology toxicity.
  
  
  CONCLUSIONS
  Gifitinib shows more superiority for non-small cell lung cancer, and its clinical application is worthy to be advocated.
authors.affiliation: Evidence-Based Medicine Center of Lanzhou University, School of Basic Medical Science, Lanzhou University, Lanzhou, China.
authors.forename: Jiwu
authors.initials: J
authors.lastname: Guo
authors.forename: Bin
authors.initials: B
authors.lastname: Ma
authors.forename: Huiyin
authors.initials: H
authors.lastname: Zhou
authors.forename: Yao
authors.initials: Y
authors.lastname: Wang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011786:Quality Control; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib